Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients

What Was Tested

The trial (not phased) is built around Exenatide and Liraglutide for psoriasis and psoriatic arthritis.

The aim of the study is to evaluate after 4 to 6 months the effects of a GLP-1 analog treatment on psoriatic skin lesions in patients with type 2 diabetes.

It had 1 arm (groups): GLP-1 analog (experimental).

The registry classes the interventions as drug.

Who Took Part

The registry lists 10 actual participants took part.

It was open to people of any sex aged from 20 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

The full record lists 1 inclusion and 4 exclusion criteria; among the exclusions: type 1 diabetes; secondary diabetes; liver, renal or pancreatic disease.

How the Study Was Run

It was run as a single-group and open-label study.

Everyone knew when Exenatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2012-01 with completion listed for 2012-12.

It ran at 1 site in Belgium.

Its stated primary purpose is treatment.

What Was Measured

It also tracked 6 secondary outcomes, for example Evolution of BMI (body mass index), Evolution of immunological data, Evolution of histopathological data, Evolution of glycaemic control, Evolution of routine laboratory measures and Evolution of BMI.

What This Means in Plain Language

Put simply, this is a not phased trial of Exenatide and Liraglutide in 10 people with psoriasis and psoriatic arthritis.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Exenatide compound page and the Liraglutide compound page, Psoriasis and psoriatic arthritis research.